140 related articles for article (PubMed ID: 32197918)
1. Feasibility of using dynamic contrast-enhanced MRI for differentiating thymic carcinoma from thymic lymphoma based on semi-quantitative and quantitative models.
Shen J; Xue L; Zhong Y; Wu YL; Zhang W; Yu TF
Clin Radiol; 2020 Jul; 75(7):560.e19-560.e25. PubMed ID: 32197918
[TBL] [Abstract][Full Text] [Related]
2. Quantitative texture analysis based on dynamic contrast enhanced MRI for differential diagnosis between primary thymic lymphoma from thymic carcinoma.
Zhu JJ; Shen J; Zhang W; Wang F; Yuan M; Xu H; Yu TF
Sci Rep; 2022 Jul; 12(1):12629. PubMed ID: 35871647
[TBL] [Abstract][Full Text] [Related]
3. Quantitative dynamic contrast-enhanced and diffusion-weighted MRI for differentiation between nasopharyngeal carcinoma and lymphoma at the primary site.
Yu XP; Hou J; Li FP; Xiang W; Lu Q; Hu Y; Wang H
Dentomaxillofac Radiol; 2016; 45(3):20150317. PubMed ID: 26846711
[TBL] [Abstract][Full Text] [Related]
4. Combined diffusion-weighted imaging and dynamic contrast-enhanced MRI for differentiating radiologically indeterminate malignant from benign orbital masses.
Xu XQ; Qian W; Ma G; Hu H; Su GY; Liu H; Shi HB; Wu FY
Clin Radiol; 2017 Oct; 72(10):903.e9-903.e15. PubMed ID: 28501096
[TBL] [Abstract][Full Text] [Related]
5. Value of quantitative multiparametric MRI in differentiating pleomorphic adenomas from malignant epithelial tumors in lacrimal gland.
Wang Y; Song L; Guo J; Xian J
Neuroradiology; 2020 Sep; 62(9):1141-1147. PubMed ID: 32430642
[TBL] [Abstract][Full Text] [Related]
6. Application of Dynamic Contrast-Enhanced MRI Parameters for Differentiating Squamous Cell Carcinoma and Malignant Lymphoma of the Oropharynx.
Park M; Kim J; Choi YS; Lee SK; Koh YW; Kim SH; Choi EC
AJR Am J Roentgenol; 2016 Feb; 206(2):401-7. PubMed ID: 26797371
[TBL] [Abstract][Full Text] [Related]
7. Utility of dynamic contrast-enhanced magnetic resonance imaging for differentiating glioblastoma, primary central nervous system lymphoma and brain metastatic tumor.
Lu S; Gao Q; Yu J; Li Y; Cao P; Shi H; Hong X
Eur J Radiol; 2016 Oct; 85(10):1722-1727. PubMed ID: 27666608
[TBL] [Abstract][Full Text] [Related]
8. Prediction of the response of ocular adnexal lymphoma to chemotherapy using combined pretreatment dynamic contrast-enhanced and diffusion-weighted MRI.
Guo P; Liu Z; Yan F; Wang J; Wei L; Lv H; Wang Z; Xian J
Acta Radiol; 2016 Dec; 57(12):1490-1496. PubMed ID: 27012277
[TBL] [Abstract][Full Text] [Related]
9. Multiparametric approach with diffusion-weighted imaging and dynamic contrast-enhanced MRI: a comparison study for differentiating between benign and malignant bone lesions in adults.
Oh E; Yoon YC; Kim JH; Kim K
Clin Radiol; 2017 Jul; 72(7):552-559. PubMed ID: 28325514
[TBL] [Abstract][Full Text] [Related]
10. Dynamic contrast-enhanced MRI in orbital lymphoproliferative disorders: Effects of region of interest selection methods on time efficiency, measurement reproducibility, and diagnostic ability.
Qian W; Xu XQ; Hu H; Su GY; Wu JF; Shi HB; Wu FY
J Magn Reson Imaging; 2018 May; 47(5):1298-1305. PubMed ID: 28922524
[TBL] [Abstract][Full Text] [Related]
11. Differentiation between orbital malignant and benign tumors using intravoxel incoherent motion diffusion-weighted imaging: Correlation with dynamic contrast-enhanced magnetic resonance imaging.
Xu XQ; Hu H; Su GY; Liu H; Wu FY; Shi HB
Medicine (Baltimore); 2019 Mar; 98(12):e14897. PubMed ID: 30896639
[TBL] [Abstract][Full Text] [Related]
12. Grading of pancreatic neuroendocrine neoplasms using pharmacokinetic parameters derived from dynamic contrast-enhanced MRI.
Zhao W; Quan Z; Huang X; Ren J; Wen D; Zhang G; Shi Z; Yin H; Huan Y
Oncol Lett; 2018 Jun; 15(6):8349-8356. PubMed ID: 29805568
[TBL] [Abstract][Full Text] [Related]
13. Iodine Quantification Using Dual-Energy Computed Tomography for Differentiating Thymic Tumors.
Yan WQ; Xin YK; Jing Y; Li GF; Wang SM; Rong WC; Xiao G; Lei XB; Li B; Hu YC; Cui GB
J Comput Assist Tomogr; 2018; 42(6):873-880. PubMed ID: 30339550
[TBL] [Abstract][Full Text] [Related]
14. Differentiation of Benign from Malignant Adnexal Masses by Dynamic Contrast-Enhanced MRI (DCE-MRI): Quantitative and Semi-quantitative analysis at 3-Tesla MRI.
Gity M; Parviz S; Saligheh Rad H; Fathi Kazerooni A; Shirali E; Shakiba M; Baikpour M
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1073-1079. PubMed ID: 31030476
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiation Between Primary Central Nervous System Lymphoma and Glioblastoma.
Lu S; Wang S; Gao Q; Zhou M; Li Y; Cao P; Hong X; Shi H
J Comput Assist Tomogr; 2017; 41(6):898-903. PubMed ID: 28806317
[TBL] [Abstract][Full Text] [Related]
16. Orbital benign and malignant lymphoproliferative disorders: Differentiation using semi-quantitative and quantitative analysis of dynamic contrast-enhanced magnetic resonance imaging.
Hu H; Xu XQ; Liu H; Hong XN; Shi HB; Wu FY
Eur J Radiol; 2017 Mar; 88():88-94. PubMed ID: 28189215
[TBL] [Abstract][Full Text] [Related]
17. Dynamic contrast-enhanced MRI can quantitatively identify malignant transformation of sinonasal inverted papilloma.
Li Z; Xian M; Guo J; Wang CS; Zhang L; Xian J
Br J Radiol; 2022 Jun; 95(1134):20211374. PubMed ID: 35234501
[TBL] [Abstract][Full Text] [Related]
18. Comparison of CT and chemical-shift MRI for differentiating thymoma from non-thymomatous conditions in myasthenia gravis: value of qualitative and quantitative assessment.
Priola AM; Priola SM; Gned D; Giraudo MT; Fornari A; Veltri A
Clin Radiol; 2016 Mar; 71(3):e157-69. PubMed ID: 26774127
[TBL] [Abstract][Full Text] [Related]
19. Role of dynamic contrast-enhanced MRI in predicting severe acute radiation-induced rectal injury in patients with rectal cancer.
Chen Y; Ding L; Zhang ZW; Wu XH; Que YT; Ma YR; Liu YY; Wen ZQ; Yang XY; Lu BL; Bao Y; Niu SQ; Yu SP
Eur Radiol; 2024 Mar; 34(3):1471-1480. PubMed ID: 37665390
[TBL] [Abstract][Full Text] [Related]
20. Preoperative histogram parameters of dynamic contrast-enhanced MRI as a potential imaging biomarker for assessing the expression of Ki-67 in prostate cancer.
Zhang Y; Li Z; Gao C; Shen J; Chen M; Liu Y; Cao Z; Pang P; Cui F; Xu M
Cancer Med; 2021 Jul; 10(13):4240-4249. PubMed ID: 34117733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
